Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
61
TWST Quote, Financials, Valuation and Earnings
Last price:
$41.20
Seasonality move
:
-11.93%
Day range:
$38.65 - $40.90
52-week range:
$23.30 - $55.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.39x
P/B ratio:
5.19x
Volume:
1.2M
Avg. volume:
1.2M
1-year change:
-6.36%
Market cap:
$2.5B
Revenue:
$376.6M
EPS (TTM):
-$1.31
Analysts' Opinion
-
Consensus RatingTwist Bioscience Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $39.00, Twist Bioscience Corp. has an estimated downside of -2.57% from its current price of $40.03.
-
Price Target UpsideAccording to analysts, the highest upside price target is $43.00 representing 7.42% upside increase from its current price of $40.03.
Fair Value
-
According to the consensus of 9 analysts, Twist Bioscience Corp. has -2.57% downside to fair value with a price target of $39.00 per share.
TWST vs. S&P 500
-
Over the past 5 trading days, Twist Bioscience Corp. has overperformed the S&P 500 by 10.15% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Twist Bioscience Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Twist Bioscience Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Twist Bioscience Corp. reported revenues of $99M.
Earnings Growth
-
Twist Bioscience Corp. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Twist Bioscience Corp. reported earnings per share of -$0.45.
Enterprise value:
2.3B
EV / Invested capital:
--
Price / LTM sales:
6.39x
EV / EBIT:
--
EV / Revenue:
6.10x
PEG ratio (5yr expected):
-3.49x
EV / Free cash flow:
-30.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$191M
Return On Assets:
-12.51%
Net Income Margin (TTM):
-20.63%
Return On Equity:
-16.74%
Return On Invested Capital:
-14.27%
Operating Margin:
-30.24%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $245.1M | $313M | $376.6M | $84.7M | $99M | |
| Gross Profit | $89.7M | $133.3M | $191M | $38.2M | $50.8M | |
| Operating Income | -$206.9M | -$175.9M | -$136.3M | -$36M | -$29.9M | |
| EBITDA | -$176.5M | -$144.5M | -$111.7M | -$29.4M | -$23.9M | |
| Diluted EPS | -$3.60 | -$3.60 | -$1.31 | -$0.59 | -$0.45 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $546.5M | $596.5M | $424.3M | $346.8M | $333M | |
| Total Assets | $702.1M | $961.4M | $776.4M | $614.3M | $641.9M | |
| Current Liabilities | $63.1M | $90.7M | $73.3M | $71M | $91.4M | |
| Total Liabilities | $121.3M | $172M | $153M | $141.6M | $168.9M | |
| Total Equity | $580.8M | $789.4M | $623.4M | $472.7M | $473M | |
| Total Debt | $54.7M | $81.3M | $79.2M | $70.2M | $61.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$142.5M | -$64.1M | -$47.6M | -$15.3M | -$11.8M | |
| Cash From Investing | $50.6M | -$3.1M | -$24.8M | -$1.3M | -$12.4M | |
| Cash From Financing | $911K | $6.9M | $28.5M | $3.6M | $5.6M | |
| Free Cash Flow | -$170.3M | -$69.2M | -$75.6M | -$17.3M | -$24.2M | |
TWST
Sector
Market Cap
$2.5B
$27.1M
Price % of 52-Week High
72.34%
51.93%
Dividend Yield
0%
0%
Shareholder Yield
-0.66%
-1.63%
1-Year Price Total Return
-6.36%
-15.41%
Beta (5-Year)
2.191
0.489
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$37.01
200-day SMA
Buy
Level
$32.23
Bollinger Bands (100)
Buy
Level
27.19 - 33.75
Chaikin Money Flow
Buy
Level
47.3M
20-day SMA
Buy
Level
$34.42
Relative Strength Index (RSI14)
Buy
Level
69.81
ADX Line
Buy
Level
25.47
Williams %R
Sell
Level
-12.6692
50-day SMA
Buy
Level
$31.93
MACD (12, 26)
Buy
Level
1.89
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Sell
Level
-3.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.5204)
Buy
CA Score
(Annual)
Level (-0.0473)
Buy
Beneish M-Score
(Annual)
Level (-2.2862)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.6246)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, TWST has received 7 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TWST average analyst price target in the past 3 months is $39.00.
-
Where Will Twist Bioscience Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Twist Bioscience Corp. share price will drop to $39.00 per share over the next 12 months.
-
What Do Analysts Say About Twist Bioscience Corp.?
Analysts are divided on their view about Twist Bioscience Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Twist Bioscience Corp. is a Sell and believe this share price will rise from its current level to $33.00.
-
What Is Twist Bioscience Corp.'s Price Target?
The price target for Twist Bioscience Corp. over the next 1-year time period is forecast to be $39.00 according to 9 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is TWST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Twist Bioscience Corp. is a Buy. 7 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TWST?
You can purchase shares of Twist Bioscience Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Twist Bioscience Corp. shares.
-
What Is The Twist Bioscience Corp. Share Price Today?
Twist Bioscience Corp. was last trading at $41.20 per share. This represents the most recent stock quote for Twist Bioscience Corp.. Yesterday, Twist Bioscience Corp. closed at $40.03 per share.
-
How To Buy Twist Bioscience Corp. Stock Online?
In order to purchase Twist Bioscience Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TWST Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TWST
Sector
P/E ratio
--
23.89x
PEG ratio
-3.49x
-0.01x
P/B ratio
5.19x
1.82x
Price / LTM sales
6.39x
1.60x
Growth Metrics
TWST
Sector
Revenue growth
16.88%
4.35%
Earnings growth
24.11%
9.95%
Revenue (5-year growth)
33.11%
6.41%
Earnings forecast
-$0.52
-$0.18
Profitability
TWST
Sector
Profitability FY 2025
$191M
$3.4M
Return on invested capital
-14.27%
-32.69%
Return on assets
-12.51%
-29%
Return on equity
-16.74%
-38.43%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Feb
2
Estimated Next Earnings Date
Feb
13
Balance Sheet
TWST
Sector
Total cash
$232.4M
$25.7M
Short term investments
$50.1M
$25.5M
Total assets
$641.9M
$75.6M
Long term debt
$61.8M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
53
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
80
BNR alert for Jan 15
Burning Rock Biotech Ltd. [BNR] is up 11.92% over the past day.
Sell
37
TCOM alert for Jan 15
Trip.com Group Ltd. [TCOM] is down 2.66% over the past day.
Sell
39
DAVE alert for Jan 15
Dave, Inc. [DAVE] is up 3.64% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
